

Table S1. Baseline characteristics according to tumor-infiltrating lymphocyte levels.

| Variables | low TIL levels | high TIL levels | Total | <i>P</i> value |
|--------------------------|----------------|-----------------|------------|----------------|
| Age | | | | 0.653 |
| < 50 | 90 (48.9) | 56 (46.3) | 146 (47.9) | |
| ≥ 50 | 94 (51.1) | 65 (53.7) | 159 (52.1) | |
| HG* | | | | 0.001 |
| 1 or 2 | 161 (87.5) | 86 (72.9) | 247 (81.8) | |
| 3 | 23 (12.5) | 32 (27.1) | 55 (18.2) | |
| HR | | | | 0.011 |
| positive | 99 (53.8) | 47 (38.8) | 146 (47.9) | |
| negative | 85 (46.2) | 74 (61.2) | 159 (52.1) | |
| ER expression | | | | 0.034 |
| ≥ 10% | 85 (46.2) | 39 (32.2) | 124 (40.7) | |
| 1-9% | 14 (7.6) | 8 (6.6) | 22 (7.2) | |
| 0 | 85 (46.2) | 74 (61.2) | 159 (52.1) | |
| PR expression | | | | 0.087 |
| ≥ 10% | 43 (23.4) | 18 (14.9) | 61 (20.0) | |
| 1-9% | 18 (9.8) | 8 (6.6) | 26 (8.5) | |
| 0 | 123 (66.8) | 95 (78.5) | 218 (71.5) | |
| HER2 | | | | 0.870 |
| IHC 2+ | 41 (61.2) | 143 (60.1) | 184 (60.3) | |
| IHC 3+ | 26 (38.8) | 95 (39.9) | 121 (39.7) | |
| Clinical T stage | | | | 0.026 |
| 1 | 4 (2.2) | 4 (3.3) | 8 (2.6) | |
| 2 | 97 (52.7) | 81 (66.9) | 178 (58.4) | |
| ≥ 3 | 83 (45.1) | 36 (29.8) | 119 (39.0) | |
| Clinical nodal status | | | | 0.207 |
| negative | 43 (23.4) | 21 (17.4) | 64 (21.0) | |
| positive | 141 (76.6) | 100 (82.6) | 241 (79.0) | |
| Ki-67 (%)*, median (IQR) | 30 (20-60) | 45 (20-70) | 30 (20-60) | 0.200 |

*Missing value

TIL = tumor-infiltrating lymphocyte, HG = histologic grade, HER2 = human-epidermal growth receptor factor 2, HR = hormone receptor, ER = estrogen receptor, PR = progesterone receptor, IHC = immunohistochemistry.